文献速递慢性肾脏病遗传性与小管间质肾病

小干扰RNA沉默ALAS1治疗与肾功能下降

Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1).
PubMed 文献 · Kidney Int Rep · 2021-04-15

法国描述性病例系列分析20例接受givosiran治疗的急性间歇性卟啉病患者,90%在起始治疗后3个月内出现短暂肾功能下降,但无急性肾损伤或肾病证据。ENVISION队列随访至少30个月,部分患者eGFR年均下降3.4或5.8 ml/min/1.73 m²,无活动性肾小管或肾小球损伤生化证据。

要点

  • givosiran治疗3个月内多数患者出现短暂血肌酐升高,但无急性肾损伤。
  • 长期随访部分患者eGFR年均下降3.4–5.8 ml/min/1.73 m²,需监测肾功能。
  • 急性间歇性卟啉病本身促慢性肾脏病,难以区分药物长期影响与自然病程。

核心结论

  • Givosiran与短暂中度血肌酐升高相关,无肾损伤证据,但不能排除ALAS1抑制对肾功能的长期不良影响。

研究设计与样本

  • 法国描述性病例系列,纳入2018年3月至2020年7月接受givosiran治疗的20例患者(ENVISION试验7例,合作中心13例)。

主要发现

  • 20例中18例(90%)在givosiran起始后3个月内出现短暂肾功能下降,无患者发生急性肾损伤或肾病。
  • ENVISION队列随访至少30个月:2例eGFR无下降,3例平均每年下降3.4 ml/min/1.73 m²,2例平均每年下降5.8 ml/min/1.73 m²。
  • 无患者出现活动性肾小管或肾小球损伤的生化证据;1例肾活检未发现活动性肾病,肾小管ALAS1表达正常。

临床怎么用

  • 使用givosiran期间应监测血肌酐和eGFR,尤其关注起始后3个月内及长期随访。
  • 肾功能下降时需鉴别药物影响与急性间歇性卟啉病相关慢性肾脏病自然进展。

局限性

  • 样本量小(20例),为描述性病例系列,无对照组。
  • 急性间歇性卟啉病本身促慢性肾脏病,难以区分givosiran长期效应与疾病自然病程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Givosiran is an RNA interference therapeutic designed to block the synthesis of the aminolevulinic acid (ALA) synthase 1 (ALAS1) enzyme in patients with acute intermittent porphyria (AIP). Givosiran may have adverse effects on the kidney. METHODS: We performed a descriptive case series of renal function parameters of all the patients who received givosiran in France. Twenty patients receiving givosiran between March 2018 and July 2020 in France were analyzed: 7 patients in the ENVISION trial and 13 patients treated in collaboration with the Centre de Référence Maladies Rares Prophyries. RESULTS: A transient decrease in renal function was observed in all but 2 patients (90%) within the 3 months following givosiran initiation. None of the patients developed acute kidney injury or disease. Patients of the ENVISION cohort were followed for at least 30 months: 2 patients did not experience estimated glomerular filtration rate (eGFR) loss, 3 patients experienced a modest decline in renal function (-3.4 ml/min per 1.73 m2 per year in average), and 2 patients had a clearly abnormal eGFR loss (-5.8 ml/min per 1.73 m2 per year in average). None of the patients had biochemical signs of active tubular or glomerular injury. One patient's kidney was biopsied without finding any signs of an active kidney disease and with normal ALAS1 tubular expression. CONCLUSIONS: Givosiran is associated with a transient moderate increase in serum creatinine (sCr) without sign of kidney injury. A long-term deleterious impact of ALAS1 inhibition on renal function is not excluded. Because AIP promotes chronic kidney disease, it is difficult to separate the long-term effects of givosiran from the natural progression of the renal disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lazareth H, Poli A, Bignon Y, et al. Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1). Kidney Int Rep. 2021. PMID: 34307985. doi:10.1016/j.ekir.2021.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。